Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Ariella who wrote (901)	6/13/1998 8:32:00 PM
From: cm	Read Replies (1) \| Respond to of 1491

FWIW, Which I Fear Is Precious Little... Last week, I sent an e-mail to Pharmos asking a question that was personally important to me about any possible HU-211 applications for post-polio... because my brother suffers from this degenerative condition. Within two days, Gad Reisenfeld, responded with, in part, this message... "... Dexanabinol is a broad-based neuroprotectant and anti-inflammatory. It has shown neuroprotection in many animal models for potentially various indications. We also test many analogs for other potential neurological indications. It will take, however, many years to develop the products and there is no guarantee of success. I cannot comment specifically on ALS and post-polio applications." While, for sure, this tells INVESTORS nothing new, I respect the company's prompt response to my question. Further, I respect the fact that Gad was very circumspect in his answer about possible indications for HU-211. Not particularly heartening for my brother, but... what can you say? Best Regards, PARSians c m